2024 World Conference on Lung Cancer (WCLC) - Posters-P2.14A.01 Clinicopathological Characteristics and Treatment Outcomes of Patients with Advanced SMARCA4-Deficient Non-Small Cell Lung Cancer

P2.14A.01 Clinicopathological Characteristics and Treatment Outcomes of Patients with Advanced SMARCA4-Deficient Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study conducted by Hui Liu at the Sun Yat-sen University Cancer Center investigates advanced SMARCA4-deficient non-small cell lung cancer (SD-NSCLC), a variant distinguished by its high invasiveness and poor prognosis, which is resistant to standard treatments. This retrospective study aims to examine the clinicopathological and genomic profiles of these patients and evaluate their response to immune checkpoint inhibitors (ICIs) and local therapies (radiotherapy or surgery).<br /><br />The study involved 53 patients with stage III or IV SD-NSCLC, who had a follow-up period exceeding six months. Clinical and genetic data were collected, revealing significant mutations in 39.6% of the patients. These patients were divided into groups based on treatment types: those receiving ICIs, non-ICIs, local treatment, and non-local treatment.<br /><br />Key findings include the fact that stage IV patients treated with ICIs demonstrated a significantly improved median progression-free survival (mPFS) compared to those who did not receive ICIs (7 months vs. 3 months, P=0.021). Although the median overall survival (mOS) displayed an increasing trend for ICI-treated patients, it was not statistically significant. In stage III patients, both mPFS and mOS showed no significant difference between ICI and non-ICI regimens.<br /><br />Furthermore, in stage III cases, patients who underwent local treatment exhibited significantly longer mPFS than those who did not (9 months vs. 2 months, P=0.012), although mOS was not significantly improved. Local treatment in stage IV patients did not show marked improvements in either mPFS or mOS.<br /><br />The study concludes that ICI therapy represents a potentially effective treatment strategy for advanced SD-NSCLC and highlights the value of local treatment in stage III patients. The findings suggest a nuanced approach to treating this challenging cancer subgroup, noting variances in treatment efficacy across different disease stages.

Asset Subtitle

hui liu

Meta Tag

Speaker hui liu

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

SMARCA4-deficient

non-small cell lung cancer

immune checkpoint inhibitors

local therapies

clinicopathological profiles

genomic profiles

progression-free survival

overall survival

treatment efficacy

advanced cancer